Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

MorphoSys And Novozymes Sign Long-Term Alliance On Slonomics Technology

MorphoSys AG (MPSYY.PK) and Novozymes A/S Thursday said they have signed a multi-year licensing and technology transfer agreement. The agreement provides Novozymes with a non-exclusive license to use MorphoSys's proprietary Slonomics technology to develop novel products within the industrial biotechnology sector.

Novozymes becomes the first industrial biotech company to have access to Slonomics technology. Financial details were not disclosed.

Slonomics technology, which comprises patented methods and know-how, advanced materials and robotic equipment, allows combination of building blocks in exactly the preferred order and composition. Researchers can thus create only the desired diversity among a set of enzyme variants, eliminating all the undesired combinations. In a typical scenario, Novozymes' researchers can reduce the number of variants made from millions to ten thousand.

Click here to receive FREE breaking news email alerts for MorphoSys AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Suggesting that the economy is gaining traction, the Conference Board released a report on Thursday showing a bigger than expected increase by its index of leading U.S. economic indicators in July. Results of a survey released by the Federal Reserve Bank of Philadelphia on Thursday showed that regional manufacturing activity unexpectedly grew at an accelerated rate in the month of August, with the index of activity in the sector reaching a three-year high. Existing home sales in U.S. unexpectedly rose to a ten-month high in the month of July, according to a report released by the National Association of Realtors on Thursday. NAR said existing home sales climbed to a seasonally adjusted annual rate of 5.15 million in July from a downwardly revised 5.03 million in June.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.